Patent · US Active

Amanitin antibody conjugates

US11446388B2 · kind B2 · utility

0Cited by

2References

3Claims

0Family size

Assignee

Heidelberg Pharma Research GmbH · DE

Inventors

Torsten Hechler · Ladenburg, DE
Michael Kulke · Ladenburg, DE
Christian Lutz · Kassel, DE
Andreas Pahl · Ladenburg, DE
Christoph Müller · Birkenau, DE
Werner Simon · Seeheim-Jugenheim, DE
Anikó Pálfi · Ladenburg, DE

Key dates

Filing date	Dec 22, 2017
Grant date	Sep 20, 2022
Priority date	—
Expiry date	Mar 15, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K16/2878
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to a conjugate comprising (a) an amatoxin comprising (i) an amino acid 4 with a 6′-deoxy position; and (ii) an amino acid 8 with an S-deoxy position; (b) a BCMA-binding moiety comprising (i) the variable domains of humanized antibody J22.9-ISY, and (ii) a heavy chain constant region comprising a D265C mutation; and (c) a protease-cleavable linker linking said amatoxin and said target-binding moiety. The invention furthermore relates to a pharmaceutical composition comprising such conjugate, particularly for use in the treatment of multiple myeloma.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.